| HUMAN-TRIAL | evidence | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Tirzepatide | Glycemic control · human-rct · n = 148 | — |
| HUMAN-TRIAL | evidence | Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity | Mounjaro | Weight & fat loss · human-observational · n = 154 | — |
| HUMAN-TRIAL | evidence | An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Tirzepatide | Weight & fat loss · n = 45 | — |
| HUMAN-TRIAL | evidence | Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | Mounjaro | Weight & fat loss · n = 8 | — |
| HUMAN-TRIAL | evidence | Tirzepatide in PWS, HO and GNSO | Tirzepatide | Weight & fat loss · human-observational · n = 36 | — |
| HUMAN-TRIAL | evidence | Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Tirzepatide | Addiction & substance use · human-rct · n = 176 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | LY-3298176 | Glycemic control · human-rct · n = 257 | — |
| HUMAN-TRIAL | evidence | The Long COVID Treatment Trial | Tirzepatide | human-rct · n = 1000 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Tirzepatide for Weight Management | Tirzepatide | Weight & fat loss · n = 440 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide in Overweight and Very Overweight Participants | LY-3298176 | Weight & fat loss · human-rct · n = 114 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Tirzepatide | Weight & fat loss · human-rct · n = 372 | — |
| HUMAN-TRIAL | evidence | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | LY-3298176 | human-rct · n = 350 | — |
| HUMAN-TRIAL | evidence | Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity | Tirzepatide | human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | Tirzepatide | human-observational · n = 887132 | — |
| HUMAN-TRIAL | evidence | Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Tirzepatide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | LY-3298176 | Kidney function · human-rct · n = 45 | — |
| HUMAN-TRIAL | evidence | Tirzepatide in MetALD | Tirzepatide | Addiction & substance use · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) | Tirzepatide | Weight & fat loss · human-observational · n = 364 | — |
| HUMAN-TRIAL | evidence | Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data | Tirzepatide | human-observational · n = 44671 | — |
| HUMAN-TRIAL | evidence | Tirzepatide Use in People With Obesity and Type 1 Diabetes | Tirzepatide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | LY-3298176 | Weight & fat loss · human-rct · n = 731 | — |
| HUMAN-TRIAL | evidence | Multi-Site Trial of Tirzepatide for Smoking Cessation | Tirzepatide | Addiction & substance use · human-rct · n = 300 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | Tirzepatide | Weight & fat loss · human-rct · n = 354 | — |
| HUMAN-TRIAL | evidence | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | Tirzepatide | human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | LY-3298176 | Weight & fat loss · human-rct · n = 2539 | — |
| HUMAN-TRIAL | evidence | Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | Tirzepatide | Weight & fat loss · human-rct · n = 66 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | LY-3298176 | Glycemic control · human-rct · n = 1879 | — |
| HUMAN-TRIAL | evidence | Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Tirzepatide | Weight & fat loss · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | Tirzepatide | Addiction & substance use · n = 40 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants | LY-3298176 | human-rct · n = 47 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | LY-3298176 | Glycemic control · human-rct · n = 117 | — |
| HUMAN-TRIAL | evidence | Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes | Tirzepatide | Glycemic control · human-rct · n = 150 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | LY-3298176 | Weight & fat loss · human-rct · n = 3000 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | LY-3298176 | Liver health · human-rct · n = 190 | — |
| HUMAN-TRIAL | evidence | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Zepbound | Weight & fat loss · human-observational · n = 125000 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | LY-3298176 | Glycemic control · human-rct · n = 1444 | — |
| HUMAN-TRIAL | evidence | A Study of LY3841136 in Overweight and Obese Participants | Tirzepatide | Weight & fat loss · human-rct · n = 96 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | LY-3298176 | Weight & fat loss · n = 344 | — |
| HUMAN-TRIAL | evidence | Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Tirzepatide | Weight & fat loss · human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide in Participants With Impaired Liver Function | LY-3298176 | human-observational · n = 32 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | LY-3298176 | Glycemic control · human-rct · n = 111 | — |
| HUMAN-TRIAL | evidence | Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss | Mounjaro | Weight & fat loss · human-rct · n = 42 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction | Tirzepatide | Glycemic control · human-observational · n = 28118 | — |
| HUMAN-TRIAL | evidence | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Tirzepatide | Weight & fat loss · n = 30 | — |
| HUMAN-TRIAL | evidence | Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | Tirzepatide | Weight & fat loss · human-rct · n = 24 | — |
| HUMAN-TRIAL | evidence | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Tirzepatide | n = 55 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | LY-3298176 | Weight & fat loss · human-rct · n = 905 | — |
| HUMAN-TRIAL | evidence | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Tirzepatide | Glycemic control · human-observational · n = 70000 | — |
| HUMAN-TRIAL | evidence | Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data | Tirzepatide | Glycemic control · human-observational · n = 11265 | — |
| HUMAN-TRIAL | evidence | A Study of Tirzepatide (LY3298176) in Healthy Lactating Females | LY-3298176 | n = 11 | — |